miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression

RNA-based therapeutics could represent a new avenue of cancer treatment. miRNA 331-3p (miR-331-3p) is implicated in prostate cancer (PCa) as a putative tumor suppressor, but its functional activity and synergy with other anti-tumor agents is largely unknown. We found miR-331-3p expression in PCa tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Epis, Michael R., Giles, Keith M., Beveridge, Dianne J., Richardson, Kirsty L., Candy, Patrick A., Stuart, Lisa M., Bentel, Jacqueline, Cohen, Ronald J., Leedman, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589646/
https://www.ncbi.nlm.nih.gov/pubmed/28903407
http://dx.doi.org/10.18632/oncotarget.18664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589646/
https://www.ncbi.nlm.nih.gov/pubmed/28903407
http://dx.doi.org/10.18632/oncotarget.18664

Ejemplares similares